We’ve posted a new article on the Bioentrepreneur home page, investigating the costs of going public for small companies. You can access both the HTML and PDF versions here. The author is Mark Kessel, who writes for Nature Biotechnology on occasion, including here (on Sarbanes-Oxley) and here (pharma’s troubled business model). He’s also hosted one of our Bioentrepreneur “Meet the Author” discussions, which you can find here.
Recent comments on this blog
New Trump Travel Ban a Detriment to Biotech
More on the Shelf
My Biotech Heroes